NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









GeneCentric

GeneCentric

Private
Durham, North CarolinaHealthcare & Life Scienceshttps://genecentric.com/

Last Round

Series C

Jun 18, 2025

Total Funding Raised

$28.25M

Company Overview

GeneCentric is a precision oncology company that develops AI-driven diagnostic solutions and RNA-based gene expression signatures to identify patient populations likely to respond to specific cancer therapeutics.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

precision medicineRNA-based diagnosticsgenomic signaturesoncology diagnosticsbiomarker platformpancreatic ductal adenocarcinomaPDACliquid biopsyclinical trial enrichmenttumor subtypingmolecular diagnosticscompanion diagnosticsclinical decision supportbiotech analyticsai-driven diagnostics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GeneCentric Comparables

Compare GeneCentric with similar companies based on industry and business-model similarity.

GeneCentric comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cofactor Genomics
82%
Exai Bio
76%
Labcorp
74%

GeneCentric Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJun 18, 2025
Series B ExtensionNov 8, 2021
Series BSep 22, 2021
VC RoundDec 22, 2016
Series AJul 22, 2014
VC Round
Jul 8, 2013

Key People

Founding team and executive leadership

Michael Milburn

CEO And President

Executive Team

Chenyqua Baldwin Shepard

Chief Operating Officer

Executive Team

GeneCentric Investors

Notable investors and investment history

GeneCentric investors
InvestorRounds
IAG Capital PartnersSeries B Extension, Series B, Series C
Hatteras Venture PartnersSeries A, Series B Extension, Series B, VC Round, Series C, Seed
Alexandria Venture InvestmentsSeries B, Series C
Alexandria Venture InvestmentsSeries B Extension, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 9, 2025

    Launched PurIST, an RNA-based tumor classification test, with Tempus.

  • Sep 9, 2025

    Collaborated with Tempus to develop and deploy PurIST RNA-based algorithm test.

GeneCentric Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

GeneCentric Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GeneCentric's valuation, stock price, and market status.

Firmographic Details

HeadquartersDurham, North Carolina
Employee Range14
Year Founded2011
Last FundingJun 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.